Despite stage migration to more organ-confined disease in the era of prostate-specific antigen, the complications of advanced prostate cancer are still relatively common. Urinary tract obstruction in advanced and metastatic prostate cancer can have a varied presentation, because it may occur in multiple anatomic locations at any point in the natural history of the disease. In all cases, management depends on the current stage of disease, technical feasibility of potential therapeutic interventions, and overall prognosis of the patient. This review highlights a practical approach to the evaluation, diagnosis, and management of obstructive uropathy from prostate cancer.
Get full access to this article
View all access options for this article.
References
1.
CatalonaWJ, SmithDS, RatliffTL, BaslerJW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA, 1993; 270:948–954.
2.
UngJO, RichieJP, ChenMHet al.Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology, 2002; 60:458–463.
3.
JemalA, SiegelR, XuJ, WardE. Cancer statistics, 2010. CA Cancer J Clin, 2010; 60:277–300.
KoubaE, WallenEM, PruthiRS. Management of ureteral obstruction due to advanced malignancy: Optimizing therapeutic and palliative outcomes. J Urol, 2008; 180:444–450.
BatlleDC, ArrudaJA, KurtzmanNA. Hyperkalemic distal renal tubular acidosis associated with obstructive uropathy. N Engl J Med, 1981; 304:373–380.
9.
FaubertPF, PorushJG. Renal Disease in the Elderly, 2nd. New York: Marcel Dekker, 1998; 441.
10.
VarenhorstE, AlundG. Urethral obstruction secondary to carcinoma of the prostate: Response to endocrine treatment. Urology, 1985; 25:354–356.
11.
FleischmannJD, CatalonaWJ. Endocrine therapy for bladder outlet obstruction from carcinoma of the prostate. J Urol, 1985; 134:498–500.
12.
MebustWK, HoltgreweHL, CockettAT, PetersPC. Transurethral prostatectomy: Immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol, 2002; 167:5–9.
13.
MazurAW, ThompsonIM. Efficacy and morbidity of “channel” TURP. Urology, 1991; 38:526–528.
14.
ThomasDJ, BalajiVJ, CoptcoatMJ, AbercrombieGF. Acute urinary retention secondary to carcinoma of the prostate. Is initial channel TURP beneficial?J R Soc Med, 1992; 85:318–319.
15.
CrainDS, AmlingCL, KaneCJ. Palliative transurethral prostate resection for bladder outlet obstruction in patients with locally advanced prostate cancer. J Urol, 2004; 171:668–671.
16.
MarszalekM, PonholzerA, RauchenwaldM, MadersbacherS. Palliative transurethral resection of the prostate: Functional outcome and impact on survival. BJU Int, 2007; 99:56–59.
17.
MasoodS, DjaladatH, KouriefsCet al.The 12-year outcome analysis of an endourethral wallstent for treating benign prostatic hyperplasia. BJU Int, 2004; 94:1271–1274.
18.
EisenbergML, ElliottSP, McAninchJW. Preservation of lower urinary tract function in posterior urethral stenosis: Selection of appropriate patients for urethral stents. J Urol, 2007; 178:2456–2461.
19.
HussainM, GreenwellTJ, ShahJ, MundyA. Long-term results of a self-expanding wallstent in the treatment of urethral stricture. BJU Int, 2004; 94:1037–1039.
20.
ShahDK, KapoorR, BadlaniGH. North American Study Group. Experience with urethral stent explantation. J Urol, 2003; 169:1398–1400.
MichiganS, CatalonaWJ. Ureteral obstruction from prostatic carcinoma: Response to endocrine and radiation therapy. J Urol, 1977; 118:733–738.
23.
PaulAB, LoveC, ChisholmGD. The management of bilateral ureteric obstruction and renal failure in advanced prostate cancer. Br J Urol, 1994; 74:642–645.
24.
SandhuDP, MayorPE, SambrookPA, GeorgeNJ. Outcome and prognostic factors in patients with advanced prostate cancer and obstructive uropathy. Br J Urol, 1992; 70:412–416.
25.
Honnens de LichtenbergM, MiskowiakJ, RolffH. Hormonal treatment of obstructed kidneys in patients with prostatic cancer. Br J Urol, 1993; 71:313–316.
26.
OefeleinMG. Prognostic significance of obstructive uropathy in advanced prostate cancer. Urology, 2004; 63:1117–1121.
27.
DowlingRA, CarrascoCH, BabaianRJ. Percutaneous urinary diversion in patients with hormone-refractory prostate cancer. Urology, 1991; 37:89–91.
28.
VillavicencioH. Quality of life of patients with advanced and metastatic prostatic carcinoma. Eur Urol, 1993; 24:118–121.
29.
O'ReillyPH. The effect of prostatic obstruction on the upper urinary tract. FitzpatrickJM, KraneRJ. The Prostate. Edinburgh: Churchill Livingstone, 1989; 111–118.
30.
SaitohH, YoshidaK, UchijimaYet al.Two different lymph node metastatic patterns of a prostatic cancer. Cancer, 1990; 65:1843–1846.
31.
MegalliMR, GurselEO, DemiragHet al.External radiotherapy in ureteral obstruction secondary to locally invasive prostatic cancer. Urology, 1974; 3:562–564.
32.
ShekarrizB, ShekarrizH, UpadhyayJet al.Outcome of palliative urinary diversion in the treatment of advanced malignancies. Cancer, 1999; 85:998–1003.
33.
DocimoSG, DewolfWC. High failure rate of indwelling ureteral stents in patients with extrinsic obstruction: Experience at 2 institutions. J Urol, 1989; 142:277–279.
34.
YossepowitchO, LifshitzDA, DekelYet al.Predicting the success of retrograde stenting for managing ureteral obstruction. J Urol, 2001; 166:1746–1749.
35.
FengMI, BellmanGC, ShapiroCE. Management of ureteral obstruction secondary to pelvic malignancies. J Endourol, 1999; 13:521–524.
36.
MarkowitzDM, WongKT, LaffeyKJet al.Maintaining quality of life after palliative diversion for malignant ureteral obstruction. Urol Radiol, 1989; 11:129–132.
37.
EyreRC, BenottiPN, BotheAet al.Management of the urinary tract involved by recurrent cancer. Arch Surg, 1987; 122:493–498.
38.
WilsonJR, UrwinGH, StowerMJ. The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl, 2005; 87:21–24.
39.
DonatSM, RussoP. Ureteral decompression in advanced nonurologic malignancies. Ann Surg Oncol, 1996; 3:393–399.
40.
GanatraAM, LoughlinKR. The management of malignant ureteral obstruction treated with ureteral stents. J Urol, 2005; 174:2125–2128.
41.
ChungSY, SteinRJ, LandsittelDet al.15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol, 2004; 172:592–595.
42.
RosevearHM, KimSP, WenzlerDLet al.Retrograde ureteral stents for extrinsic ureteral obstruction: Nine years' experience at University of Michigan. Urology, 2007; 70:846–850.
43.
LiuJS, HrebinkoRL. The use of 2 ipsilateral ureteral stents for relief of ureteral obstruction from extrinsic compression. J Urol, 1998; 159:179–181.
44.
HammM, RathertP. [Therapy of extrinsic ureteral obstruction by 2 parallel double-J ureteral stents.](Ger) Urologe A, 1999; 38:150–155.
45.
RotariuP, YohannesP, AlexianuMet al.Management of malignant extrinsic compression of the ureter by simultaneous placement of two ipsilateral ureteral stents. J Endourol, 2001; 15:979–583.
46.
HafronJ, OstMC, TanBJet al.Novel dual-lumen ureteral stents provide better ureteral flow than single ureteral stent in ex vivo porcine kidney model of extrinsic ureteral obstruction. Urology, 2006; 68:911–915.
47.
LiatsikosE, KallidonisP, KyriazisIet al.Ureteral obstruction: Is the full metallic double-pigtail stent the way to go?Eur Urol, 2010; 57:480–486.
48.
LiatsikosEN, KarnabatidisD, KagadisGCet al.Metal stents in the urinary tract. EAU-EBU Update Series, 2007; 5:77.
49.
LiatsikosEN, KarnabatidisD, KatsanosKet al.Ureteral metal stents: 10-year experience with malignant ureteral obstruction treatment. J Urol, 2009; 182:2613–2617.
50.
ChristmanMS, L'EsperanceJO, ChoeCHet al.Analysis of ureteral stent compression force and its role in malignant obstruction. J Urol, 2009; 181:392–396.
51.
BorinJF, MelamudO, ClaymanRV. Initial experience with full-length metal stent to relieve malignant ureteral obstruction. J Endourol, 2006; 20:300–304.
52.
WahTM, IrvingHC, CartledgeJ. Initial experience with the resonance metallic stent for antegrade ureteric stenting. Cardiovasc Intervent Radiol, 2007; 30:705–710.
53.
KulkarniRP, BellamyEA. A new thermo-expandable shape-memory nickel-titanium alloy stent for the management of ureteric strictures. BJU Int, 1999; 83:755–759.
AgrawalS, BrownCT, BellamyEA, KulkarniR. The thermo-expandable metallic ureteric stent: An 11-year follow-up. BJU Int, 2009; 103:372–376.
56.
LauMW, TemperleyDE, MehtaSet al.Urinary tract obstruction and nephrostomy drainage in pelvic malignant disease. Br J Urol, 1995; 76:565–569.
57.
SchmidbauerJ, KratzikC, KlinglerHCet al.Nephrovesical subcutaneous ureteric bypass: Long-term results in patients with advanced metastatic disease-improvement of renal function and quality of life. Eur Urol, 2006; 50:1073–1078.
58.
JoshiHB, AdamsS, ObadeyiOO, RaoPN. Nephrostomy tube or ‘JJ’ ureteric stent in ureteric obstruction: Assessment of patient perspectives using quality-of-life survey and utility analysis. Eur Urol, 2001; 39:695–701.
59.
RolligC, WockelA, WeissbachL. Management of obstructive uropathy patients with advanced prostate cancer—a systematic review. Onkologie, 2009; 32:680–684.
60.
KuJH, LeeSW, JeonHGet al.Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: Are there differences?Urology, 2004; 64:895–899.
ChiouRK, ChangWY, HoranJJ. Ureteral obstruction associated with prostate cancer: The outcome after percutaneous nephrostomy. J Urol, 1990; 143:957–959.
63.
BordinazzoR, BenecchiL, CazzanigaAet al.Ureteral obstruction associated with prostate cancer: The outcome after ultrasonographic percutaneous nephrostomy. Arch Ital Urol Androl, 1994; 66,suppl 4:101–106.
64.
HarrisMR, SpeakmanMJ. Nephrostomies in obstructive uropathy; how should hormone resistant prostate cancer patients be managed and can we predict who will benefit?Prostate Cancer Prostatic Dis, 2006; 9:42–44.
65.
NariculamJ, MurphyDG, JennerCet al.Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer. Br J Radiol, 2009; 82:571–576.
66.
HarringtonKJ, PandhaHS, KellySAet al.Palliation of obstructive nephropathy due to malignancy. Br J Urol, 1995; 76:101–107.
67.
RussoP. Urologic emergencies in the cancer patient. Semin Oncol, 2000; 27:284–298.
68.
RussoP. Ureteral obstruction and stents: Still a difficult problem for patients and urologists alike. J Urol, 2005; 174:2088.
69.
AravantinosE, AnagnostouT, KaratzasADet al.Percutaneous nephrostomy in patients with tumors of advanced stage: Treatment dilemmas and impact on clinical course and quality of life. J Endourol, 2007; 21:1297–1302.
